Gilead Sciences wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech outright, Gilead is paying $100 million upfront for opt-in rights on all Assembly Bio’s current and future programs.

吉利德科学公司（Gilead Sciences）希望获得所有Assembly Biosciences项目的优先权。吉利德并没有直接购买病毒性疾病生物技术公司，而是预付一亿美元，购买Assembly Bio目前和未来所有项目的选择权。

Assembly Bio has suffered a series of clinical setbacks in recent years, downgrading its goal from curing to controlling hepatitis B before dropping drug candidates altogether in response to safety signals and lackluster efficacy. With its cash falling below $60 million and its share price struggling to hit $1, the biotech had powered down parts of its pipeline to preserve cash..

Assembly Bio近年来遭遇了一系列临床挫折，将其目标从治疗降低到控制乙型肝炎，然后为了应对安全信号和疗效不佳而完全放弃候选药物。随着现金跌至6000万美元以下，股价艰难触及1美元，这家生物技术公司已经关闭了部分管道以保存现金。。

Gilead is powering Assembly Bio back up. The Big Biotech is paying $84.8 million upfront and making a $15.2 million equity investment in return for a 19.9% stake in Assembly Bio. Gilead has also agreed to buy up to a further 29.9% of the biotech’s stock.

吉利德正在为组装生物备份供电。这家大型生物技术公司预付8480万美元，并进行了1520万美元的股权投资，以换取Assembly Bio 19.9%的股份。吉利德还同意再购买该生物技术公司29.9%的股份。

“It gives us the ability to actually build a fully-fledged life sciences organization,” Assembly Bio CEO Jason Okazaki told Fierce Biotech in an interview.

Assembly Bio首席执行官冈崎骏（JasonOkazaki）在一次采访中告诉Fierce Biotech，“它使我们能够真正建立一个成熟的生命科学组织。”。

“I actually don’t think it really has any impact on our strategic ability to source things going forward,” Okazaki added. “It gives us the independence we actually need, because we are basically running all programs until the opt-in points.”

冈崎补充道：“实际上，我不认为这会对我们未来的战略采购能力产生任何影响。”。“它给了我们实际需要的独立性，因为在选择加入之前，我们基本上正在运行所有程序。”

In return for its outlay, Gilead has secured a chance to obtain exclusive rights to all Assembly Bio’s current and future programs. The opt-ins are set for the end of phase 1 or, if an extension is activated, the end of phase 2 and are worth at least $45 million per program. Beyond that, Assembly Bio is in line to receive up to $330 million in regulatory and commercial milestones per program..

作为支出的回报，吉利德获得了获得Assembly Bio当前和未来所有项目专有权的机会。选择加入被设定为第一阶段结束，或者，如果扩展被激活，则为第二阶段结束，每个项目至少价值4500万美元。除此之外，Assembly Bio有望获得每个项目高达3.3亿美元的监管和商业里程碑。。

The deal ties Assembly Bio to Gilead for 12 years. Over that time, if Gilead wants an Assembly Bio asset, it can buy it under pre-agreed terms. Yet, with Assembly Bio having its own commercial opt-in options, Okazaki sees the deal as a way for his company to “stay independent.”

该协议将Assembly Bio与吉利德联系了12年。在这段时间内，如果吉利德想要组装生物资产，它可以按照预先商定的条款购买。然而，由于Assembly Bio拥有自己的商业选择权，冈崎认为这笔交易是他的公司“保持独立”的一种方式

“The reality of most of these collaborations is … they’re not going to opt in … to everything,” Okazaki told Fierce Biotech. “Sure, they will have an opt-in on future research discoveries. But the big thing on the back end is we can opt in to the profit/cost share. On the new compounds, we also have a co-promoter option.”.

冈崎骏告诉《凶猛生物技术》：“大多数合作的现实是……他们不会选择……一切。”。“当然，他们将有权选择未来的研究发现。但后端的一件大事是我们可以选择利润/成本份额。在新化合物上，我们也有共同促进者的选择。”。

Assembly Bio will advance its own candidates alongside two programs contributed by Gilead. Okazaki is aiming to have four molecules in the clinic by the end of next year. One of the molecules, ABI-4334, is a core inhibitor that Assembly Bio paused work on in April to save money. “We would certainly plan on reinitiating that to get it to the [phase] 1b point, which would be an opt-in point,” Okazaki said..

Assembly Bio将与Gilead提供的两个项目一起推进自己的候选人。冈崎（Okazaki）的目标是在明年年底之前在临床上拥有四种分子。其中一种分子ABI-4334是一种核心抑制剂，Assembly Bio在4月份暂停了这项工作，以节省资金。冈崎说：“我们当然会计划重新启动，使其达到[阶段]1b点，这将是一个选择加入点。”。。

A push to get the hepatitis B candidate ABI-4334 into the clinic will advance alongside work to ready a pair of herpes simplex virus (HSV) therapies for human testing. Gilead is contributing a helicase-primase inhibitor, adding to Assembly Bio’s own candidate against the target and positioning it to take two HSV programs into the clinic.

推动乙型肝炎候选药物ABI-4334进入临床，同时准备一对用于人体检测的单纯疱疹病毒（HSV）疗法。吉利德正在贡献一种解旋酶引物抑制剂，将其添加到Assembly Bio针对该靶标的候选药物中，并将其定位为将两个HSV项目引入临床。

Assembly Bio’s hepatitis delta virus drug rounds out the list of near-clinic assets..

Assembly Bio的三角洲肝炎病毒药物列出了近诊所资产清单。。

The deal has echoes of Gilead’s ill-fated decision to pay $3.95 billion upfront for exclusive access to all current and future Galapagos compounds. Gilead saw the deal as a way to bolt an external innovation engine on to its own operation, doubling its research capacity. Galapagos framed the pact as a way to secure its independence and emerge as a midsized biopharma company.

这项交易呼应了吉利德（Gilead）命运不佳的决定，即预付39.5亿美元，以获得目前和未来加拉帕戈斯（Galapagos）所有建筑的独家使用权。吉利德将这笔交易视为将外部创新引擎连接到自身运营中的一种方式，使其研究能力翻了一番。加拉帕戈斯将该协议视为确保其独立性和成为中型生物制药公司的一种方式。

The situation soured quickly..

局势很快恶化。。